Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.22 - $42.57
Previous CloseN/A
Volume219.80K
Average Volume (3M)1.13M
Market Cap
$1.65B
Enterprise Value$414.73M
Total Cash (Recent Filing)$836.88M
Total Debt (Recent Filing)$7.59M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 12, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding57,597,940
10 Day Avg. Volume1,092,829
30 Day Avg. Volume1,134,156
Financial Highlights & Ratios
PEG Ratio3.15
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-12.11
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.79K
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$71.36Price Target Upside151.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Financial PositionStructure is well-capitalized with $836.9M in cash and investments, providing financial stability for ongoing research and development.
Market OpportunityThere is a substantial place for oral, small molecule GLP-1Ra’s in the rapidly expanding obesity and T2D markets, indicating a strong market potential for Structure Therapeutics.
Product DifferentiationThe potential for aleniglipron to show a differentiated safety and tolerability profile compared to orforglipron could make it an attractive acquisition target.
Bears Say
Participant RetentionApproximately 25% of participants discontinued the study for any reason across arms, indicating potential challenges with participant retention.
Transparency IssuesOur greater concern lies in the limited transparency around GI-related adverse events across dose arms.
Weight Loss QualityA 27% of weight loss was due to lean mass loss in the orfoglipron cohorts, which could raise concerns about the quality of weight loss.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $42.57 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.65B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Nov 12, 2025 which is in 34 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Aug 06, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.295 by -$0.065.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.37.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,597,940 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.295. Following the earnings report the stock price went down -0.674%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.36 (151.09% Upside)
$71.36 (151.09% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.61%
12-Months-Change
Fundamentals
Return on Equity
-21.19%
Trailing 12-Months
Asset Growth
-13.79%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$71.36
▲(151.09% Upside)
Technical Analysis
Ownership Overview
11.92% Insiders
26.95% Mutual Funds
46.09% Other Institutional Investors
14.00% Public Companies and Individual Investors